Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.
about
Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle FormulationOrigin of anti-tumor activity of the cysteine-containing GO peptides and further optimization of their cytotoxic properties.Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacyTargeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.The combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells.MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers.MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.PPARγ E3 ubiquitin ligase regulates MUC1-C oncoprotein stability.Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localizationMembrane Active Peptides and Their Biophysical Characterization
P2860
Q28394194-B33C97A1-1F20-40CA-AA91-B12AFD4E10C3Q29248355-66EA242F-B291-45E4-B866-D971D4218779Q33599115-3DE4C18B-6B66-47AB-8A37-DB6363A7D6D8Q33757061-567E9D11-41C0-4B11-A9B0-D69D30A54532Q35794436-A55AA1FD-F936-46D4-BB8A-CBCC7F5CBA96Q36621615-1F8F93F4-015C-4EE1-AF15-63275958D98EQ36928457-042A25FF-1499-471D-983A-8D5E87DD90CAQ37007099-A84D2E4D-EF8B-4010-845F-AE63F723A715Q38630691-E304D0A3-925B-45D3-B433-A8BC63834188Q38695753-7E136F0C-E3A4-4BDF-943C-9572486329BFQ39051599-1A3D9BE7-DC80-41DC-863E-8A4211C8904EQ39063057-DDC2F1BC-D389-43F9-94B5-F84ED5DD9B9CQ48146766-1F87673A-0CC4-4B0E-AABD-B9B018C1530EQ57195514-275727B6-56EF-42A0-89CE-260F9FB70494Q58717273-53BC7FF0-8BA9-46C5-A61F-7A16E52C533A
P2860
Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Inhibition of the MUC1-C oncop ...... atment of breast cancer cells.
@ast
Inhibition of the MUC1-C oncop ...... atment of breast cancer cells.
@en
type
label
Inhibition of the MUC1-C oncop ...... atment of breast cancer cells.
@ast
Inhibition of the MUC1-C oncop ...... atment of breast cancer cells.
@en
prefLabel
Inhibition of the MUC1-C oncop ...... atment of breast cancer cells.
@ast
Inhibition of the MUC1-C oncop ...... atment of breast cancer cells.
@en
P2093
P2860
P356
P1476
Inhibition of the MUC1-C oncop ...... atment of breast cancer cells.
@en
P2093
Deepak Raina
Donald Kufe
Surender Kharbanda
Yasumitsu Uchida
P2860
P304
P356
10.4161/CBT.22634
P577
2012-10-31T00:00:00Z